Clinical Practice Guideline: Shared Decision Making, Diagnostic Evaluation, and Pharmacotherapy in Type 2 Diabetes
Christina Brockamp,Rüdiger Landgraf,Ulrich Alfons Müller,Dirk Müller-Wieland,Frank Petrak,Til Uebel,the National Disease Management Guideline Group,Manfred Krüger,Martin Schulz,Andreas Klinge,Hannelore Loskill,Elke Brückel,Albrecht Dapp,Helene Klein,Jörg Westheide,Ümit Sahin,Joachim Dissemond,Sigrid Karrer,Jens Aberle,Andreas Fritsche,Bernhard Kulzer,Ludwig Merker,Stephan Morbach,Dan Ziegler,Mojtabe Ghods,Adrien Daigeler,Sabina Bülders,Günther Egidi,Stephan Fuchs,Kai Florian Mehrländer,Uwe Popert,Holger Lawall,E Sebastian Debus,Holger Diener,Martin Merkel,Knut Mai,Diana Rubin,Jutta Keller,Elke Roeb,Gerhard Rümenapf,Martin Storck,Rom Andrej Zeyfang,Anke Bahrmann,Horst Harald Klein,Nikolaus Marx,Michael Lehrke,Peter Rene Mertens,Tobias B Huber,Helmar C Lehmann,Susanne Grundke,Johannes Kruse,Peter Hübner,Christoph Schöbel,Christine Joisten,Ruth Kirschner-Hermanns,Andreas Maier-Hasselmann,Marion Burckhardt,Klaus Dieter Lemmen,Hansjürgen Agostini,Bernd Bertram,Jörg Barkhausen,Michael Uder,Elena Enax-Krumova,Andreas Fründ,Reina Tholen,Martina Schmidt,Jost Langhorst,Petra Klose,Doris Schöning,Nicola Haller,Nicolle Müller,Tatjana Pfersich,Monika Rueb,Jutta Hartmann,Ina Kopp,Monika Nothacker,Natascha Einhart,Juliane König,Katrin Krueger,Peggy Prien,Susanne Schorr,Sabine Schüler,Isabell Vader,Corinna Schaefer
DOI: https://doi.org/10.3238/arztebl.m2023.0219
2023-11-24
Abstract:Background: Type 2 diabetes is one of the most important widespread diseases worldwide. In Germany, nearly one in five persons over age 65 has type 2 diabetes. The German National Disease Management Guideline for Type 2 Diabetes (NDMG; in German: Nationale Versorgungsleitlinie, NVL) contains updated recommendations for the diagnostic evaluation and pharmacotherapy of this disease as well as information about specific groups of people for whom early detection may be useful. Methods: The guideline has been updated, chapter by chapter, since 2018. Its recommendations are based on systematically searched and evaluated scientific evidence, the clinical expertise of a multidisciplinary panel of experts, and patient perspectives. Results: The new chapter on shared decision making includes a description of a structured approach that can be used when individual treatment goals have not been achieved. The diagnosis of diabetes newly requires at least two abnormally elevated laboratory values: e.g., fasting plasma glucose ≥ 126 mg/dL (≥ 7.0 mmol/L), HbA1c ≥ 6.5 % (≥ 48 mmol/mol) and/or casual plasma glucose ≥ 200 mg/dL (≥ 11.1 mmol/L). Cardiovascular and renal risks are to be considered in the choice of drug. Studies have shown that, in persons with cardiovascular disease, treatment with GLP-1 receptor agonists (GLP-1, glucagon-like peptide-1) or SGLT2 inhibitors (SGLT2, sodium-glucose co-transporter-2) was less likely than the comparison intervention to lead to certain patient-relevant endpoints, including all-cause mortality (OR = 0.88 and 0.84, respectively), hospitalization for heart failure (SGLT2 inhibitors: OR = 0.65), and worsening of renal function (OR = 0.61 and 0.59, respectively). Conclusion: Current evidence continues to support the recommendations on pharmacotherapy of the 2021 guideline. The Guideline Group did not find evidence of adequate certainty to inform recommendations about the screening of persons at risk, HbA1c target values, or screening for sequelae and comorbidities. Better evidence on these matters would be desirable.